CNTA Centessa Pharmaceuticals
- 8.830
- -0.140-1.56%
Centessa Pharmaceuticals News
Centessa Pharmaceuticals | 10-Q: Quarterly report
Centessa Pharmaceuticals 1Q Loss/Shr 38c >CNTA
Centessa Pharmaceuticals 1Q Loss/Shr 38c >CNTA
Press Release: Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 -- Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of Serp
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively traded Invesco QQQ Trust (QQQ) was 0.6% higher in Wednesday's premarket activity, as earnings continue t
Reported Earlier, Centessa Pharmaceuticals Prices $100M Public Offering Of 10,810,810 American Depositary Shares At $9.25/ADS
Reported Earlier, Centessa Pharmaceuticals Prices $100M Public Offering Of 10,810,810 American Depositary Shares At $9.25/ADS
Centessa Pharmaceuticals Eyes $100 Million in ADS Offering
Centessa Pharmaceuticals (CNTA) said Tuesday it is seeking to raise $100 million from an underwritten public offering of American Depositary Shares, each representing one ordinary share. The proposed
Press Release: Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA
Centessa Pharmaceuticals Advances Narcolepsy Drug Trials
The FDA Has Cleared Centessa Pharmaceuticals' Investigational New Drug Application To Initiate A Phase 1 First-in-human, Clinical Trial Of ORX750 For Narcolepsy
The FDA Has Cleared Centessa Pharmaceuticals' Investigational New Drug Application To Initiate A Phase 1 First-in-human, Clinical Trial Of ORX750 For Narcolepsy
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
BOSTON and LONDON, April 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for
Buy Rating Affirmed for Centessa Pharmaceuticals Amid Promising ORX750 Prospects and Favorable Trial Results
Analysts' Top Healthcare Picks: AstraZeneca (AZN), Centessa Pharmaceuticals (CNTA)
BMO Capital Maintains Outperform on Centessa Pharmaceuticals, Maintains $15 Price Target
BMO Capital analyst Kostas Biliouris maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform and maintains $15 price target.
Centessa Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 36.67% BMO Capital $15 → $15 Maintains Outperform 11/15/2023 0.23% Jefferies $4 → $11 Upgrades
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Centessa Pharmaceuticals (CNTA)
Centessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 Results
Centessa Pharmaceuticals Q4 EPS $(0.38) Beats $(0.48) Estimate
Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.48) by 20.83 percent. This is a 15.56 percent increase over losse
Centessa Pharmaceuticals 4Q Loss/Shr 38c >CNTA
Centessa Pharmaceuticals 4Q Loss/Shr 38c >CNTA
Press Release: Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 -- Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 stu
Centessa Pharmaceuticals PLC Chief People Officer Sells Company Shares
Analysis
Price Target
No Data
